Claris Lifesciences has reported a 14.3 per cent drop in its consolidated net profit for the quarter ended June 30 2012.
Consolidated net profit stood at Rs 32.32 crore for the second quarter ended June 30, 2012, compared with Rs 37.72 crore for the same period last year. Consolidated revenues stood at Rs 195 crore for the quarter.
During the quarter, the company received three follow-up queries from the US FDA (Food and Drug Administration). The company has replied and is now awaiting a response from the USFDA.
On August 10, Aditya Sushil Kumar Handa, one of the promoters of Claris Lifesciences, sold 10 lakh shares of the drug company for an estimated Rs 16.20 crore through open market transactions. As of June quarter, Handa held 10.50 per cent stake in the drug firm.
Claris got listed in December 2010, where it raised Rs 300 crore. As on June 30, 2012, the total utilisation of the IPO proceeds stood at Rs 256 crores. Additionally commitments of another Rs 44 crores has been made, the company said.
It has commercialised 39 marketing authorisations across 23 countries during the quarter, Ciprofloxacin in Canada, Propofol (Spiva) in the Netherlands, Metronidazole in South Korea amongst others.